• Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at USD 2.48 on May 18, 2026.
• Collins sold 5,000 shares the same day for weighted average prices of about USD 39.53 to USD 41.21.
• Holdings reported as 25,000 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000007), on May 20, 2026, and is solely responsible for the information contained therein.